Homologous recombination repair (HRR) alterations may be passenger events in patients with advanced prostate cancer (PC) with high tumor mutational burden (hTMB).

被引：0
|
作者：
Bhatlapenumarthi, Vineel
De Sarkar, Navonil
Patwari, Anannya
Antonarakis, Emmanuel S.
Nelson, Ariel Ann
Kilari, Deepak
机构：
[1] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI USA
[2] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI USA
[3] Med Coll Wisconsin, Canc Ctr, Milwaukee, WI USA
[4] Univ Minnesota, Masonic Canc Ctr, Dept Med, Minneapolis, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-180; 283-11574; 3282-206-4957-326-5041; 261-566-3248-9542-9243; 3282-206-2798; 6; 4; 3; 2; 38092-33482; 38092-18853; 38092-31362; 38092-18852; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [41] Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
    Olmos, D.
    Lorente, D.
    Alameda, D.
    Cattrini, C.
    Romero-Laorden, N.
    Lozano, R.
    Lopez-Casas, P. P.
    Jambrina, A.
    Capone, C.
    Vanden Broecke, A. M.
    Trevisan, M.
    Van Sanden, S.
    Juergens, A.
    Herrera-Imbroda, B.
    Castro, E.
    ANNALS OF ONCOLOGY, 2024, 35 (05) : 458 - 472
  • [42] Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US).
    Barata, Pedro C.
    Montgomery, Rachel
    Last, Matthew
    Gillespie-Akar, Liane
    Nazari, Jonathan
    Niyazov, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [43] Profound: Phase III Study of the Efficacy and Safety of Olaparib versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair Gene (HRR) Alterations
    Feyerabend, S.
    Hussain, M.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Mehra, N.
    Goessl, C.
    Kang, J.
    Burgents, J.
    Wu, W.
    Kohlmann, A.
    Adelman, C.
    De Bono, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 71 - 72
  • [44] Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
    de Bono, J. S.
    Mateo, J.
    Fizazi, K.
    Saad, F.
    Shore, N.
    Sandhu, S.
    Chi, K. N.
    Sartor, O.
    Agarwal, N.
    Olmos, D.
    Thiery-Vuillemin, A.
    Twardowski, P.
    Roubaud, G.
    Ozguroglu, M.
    Kang, J.
    Burgents, J.
    Gresty, C.
    Corcoran, C.
    Adelman, C. A.
    Hussain, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S508 - S508
  • [45] Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.
    Sandhu, Shahneen
    Attard, Gerhardt
    Olmos, David
    Efstathiou, Eleni
    Castro, Elena
    Rathkopf, Dana E.
    Smith, Matthew Raymond
    Roubaud, Guilhem
    Small, Eric Jay
    Gomes, Andrea Juliana
    Saad, Marniza
    Tural, Deniz
    Thomas, Shibu
    Urtishak, Karen
    Gormley, Michael
    Mason, Gary
    Diorio, Brooke
    Wang, George C.
    Lopez-Gitlitz, Angela
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound.
    Thiery-Vuillemin, Antoine
    De Bono, Johann S.
    Saad, Fred
    Procopio, Giuseppe
    Shore, Neal D.
    Fizazi, Karim
    Roubaud, Guilhem
    dos Anjos, Gabriel
    Gravis, Gwenaelle
    Joung, Jae Young
    Matsubara, Nobuaki
    Castellano, Daniel
    Degboe, Arnold
    Gresty, Christopher
    Kang, Jinyu
    Allen, Allison
    Burgents, Joseph E.
    Hussain, Maha H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Alva, Ajjai Shivaram
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Halabi, Susan
    Alvarez, Ricardo H.
    Calfa, Carmen Julia
    Khalil, Maged F.
    Ahn, Eugene R.
    Cannon, Timothy Lewis
    Crilley, Pamela A.
    Fisher, Julie Gottlieb
    Haslem, Derrick S.
    Shrestha, Sagun
    Antonelli, Kaitlyn R.
    Butler, Nicole L.
    Warren, Sasha L.
    Rygiel, Andrew Lawrence
    Ranasinghe, Shamika
    Bruinooge, Suanna S.
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches
    Manneh, Ray
    Verson, Carmen Alaez
    Martin, Angel
    Delgado, Arturo
    Isaacsson Velho, Pedro H.
    Manduley, Alejandro
    Tejado, Luis
    Rodriguez, Yolanda
    Vargas, Carmen
    Barata, Pedro C.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [49] Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US).
    Barata, Pedro C.
    Montgomery, Rachel
    Last, Matthew
    Gillespie-Akar, Liane
    Nazari, Jonathan
    Arondekar, Bhakti
    Niyazov, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [50] CGP identifies largely non-overlapping high tumor mutational burden and HRD genomic alterations in 721 clinically advanced prostate acinar adenocarcinoma cases
    Dewal, Ninad
    He, Yuting
    Lee, Richard J.
    Schrock, Alexa B.
    Chung, Jon
    Hoimes, Christopher
    Chalmers, Zachary R.
    Frampton, Garrett M.
    Sun, James X.
    Lara, Primo N.
    Agrawal, Neeraj
    Matthew, Paul
    Stephens, Philip J.
    Miller, Vincent A.
    Ross, Jeffrey S.
    Ali, Siraj M.
    CANCER RESEARCH, 2017, 77
12345